 
                    
                ABIONYX Pharma
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
ABNX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012616852 (+1 more)
- LEI:
- 969500785J7VIC5YPC96
- Country:
- France
- Address:
- 33 AVENUE GEORGES POMPIDOU, 31130 BALMA
- Website:
- https://abionyx.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
ABIONYX Pharma is a new-generation biotechnology company focused on discovering and developing innovative therapies for diseases with no existing or effective treatments, including rare conditions. The company specializes in creating drugs for renal and ophthalmological diseases. It leverages its expertise in lipid science to develop novel treatments, including new High-Density Lipoprotein (HDL) vectors for targeted drug delivery and apolipoprotein A-I (apoA-I)-based therapeutics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-21 18:49 | Regulatory News Service Inside Information / Other news releases | English | 253.1 KB | ||
| 2025-10-21 18:49 | Regulatory News Service Informations privilégiées / Autres communiqués | French | 336.0 KB | ||
| 2025-09-25 18:58 | Interim Report Rapports financiers et d'audit semestriels/examens réduits / Rapport financier … | French | 1.0 MB | ||
| 2025-08-28 18:51 | Earnings Release Inside Information / Other news releases | English | 303.6 KB | ||
| 2025-08-28 18:51 | Earnings Release Informations privilégiées / Autres communiqués | French | 336.5 KB | ||
| 2025-08-27 19:26 | M&A Activity Informations privilégiées / Autres communiqués | French | 274.8 KB | ||
| 2025-08-27 19:26 | M&A Activity Inside Information / Other news releases | English | 236.5 KB | ||
| 2025-07-04 18:42 | Declaration of Voting Results & Voting Rights Announcements Total number of voting rights and capital / Information on the total number of … | English | 217.2 KB | ||
| 2025-07-04 18:42 | Declaration of Voting Results & Voting Rights Announcements Total du nombre de droits de vote et du capital / Information relative au nombr… | French | 198.1 KB | ||
| 2025-07-03 19:35 | Capital/Financing Update Acquisition ou cession des actions de l'émetteur / Information relative au cont… | French | 532.3 KB | ||
| 2025-07-03 19:35 | Capital/Financing Update Acquisition or disposal of the issuer's own shares / Information relating to th… | English | 557.0 KB | ||
| 2025-06-27 19:14 | Post-Annual General Meeting Information Inside Information / Other news releases | English | 206.8 KB | ||
| 2025-06-27 19:14 | Post-Annual General Meeting Information Informations privilégiées / Autres communiqués | French | 221.2 KB | ||
| 2025-06-06 18:15 | Pre-Annual General Meeting Information Modalités de mise à disposition des documents préparatoires à l'AG | French | 273.9 KB | ||
| 2025-06-03 18:00 | Declaration of Voting Results & Voting Rights Announcements Total du nombre de droits de vote et du capital / Information relative au nombr… | French | 198.3 KB | 
Automate Your Workflow. Get a real-time feed of all ABIONYX Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIONYX Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIONYX Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value | 
|---|---|---|---|---|---|
| 2023-02-28 | N/A | Other | Buy | 53,913 | N/A | 
 
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                     
                                        
                                    